— Know what they know.
Not Investment Advice

DYN

Dyne Therapeutics, Inc.
1W: +3.8% 1M: +22.1% 3M: -8.7% YTD: +2.6% 1Y: +53.2% 3Y: +57.4% 5Y: +17.8%
$18.98
+1.13 (+6.33%)
After Hours: $18.70 (-0.28, -1.48%)
NASDAQ · Healthcare · Biotechnology · $3.1B · Alpha Radar Strong Buy · Power 68
Smart Money Score
Bullish 75
Insider+$10.7M
Congress
ETF Holdings
Key Statistics
Market Cap$3.1B
52W Range6.36-25
Volume2,775,306
Avg Volume2,217,001
Beta1.40
Dividend
Analyst Ratings
12 Buy 1 Hold 0 Sell
Consensus Buy
Company Info
CEOJohn G. Cox
Employees192
SectorHealthcare
IndustryBiotechnology
IPO Date2020-09-17
1560 Trapelo Road
Waltham, MA 02451
US
781 786 8230
About Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Recent Insider Trades

NameTypeSharesPriceDate
Kersten Dirk S-Sale 129,672 $19.52 2026-03-11
Posner Brian S P-Purchase 2,000 $19.35 2026-03-11
Kersten Dirk S-Sale 9,482 $18.21 2026-03-10
Kersten Dirk S-Sale 219,758 $19.32 2026-03-10
Kersten Dirk S-Sale 281,858 $19.80 2026-03-10

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms